Company | Ticker | Business Description | Underwriters | Offer Date |
---|---|---|---|---|
Boundless Bio> | BOLD> | Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors. | Goldman Leerink Partners |
03/27/24 |
News Results for BOLD |
---|
US IPO Weekly Recap: Biotech leads short 3 IPO week 03/28/24 |
Oncology biotech Boundless Bio prices IPO at $16 midpoint 03/28/24 |
US IPO Week Ahead: Oncology biotech leads 3 IPO week 03/22/24 |
Oncology biotech Boundless Bio sets terms for $100 million IPO 03/21/24 |
Oncology biotech Boundless Bio files for a $100 million IPO 03/06/24 |